Phibro Animal Health Corporation (NASDAQ:PAHC)‘s stock had its “underperform” rating restated by stock analysts at Bank of America Corporation in a research note issued on Wednesday, Marketbeat reports. They currently have a $33.00 target price on the stock. Bank of America Corporation’s price target indicates a potential downside of 15.92% from the company’s previous close.

A number of other research firms have also recently weighed in on PAHC. Credit Suisse Group cut Phibro Animal Health Corporation from an “outperform” rating to a “neutral” rating and raised their price target for the company from $29.00 to $36.00 in a research note on Friday, June 2nd. Zacks Investment Research raised Phibro Animal Health Corporation from a “hold” rating to a “buy” rating and set a $38.00 price objective on the stock in a report on Thursday, May 11th. BidaskClub raised Phibro Animal Health Corporation from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 22nd. Finally, Piper Jaffray Companies set a $35.00 price target on Phibro Animal Health Corporation and gave the stock a “buy” rating in a report on Friday, July 21st. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. Phibro Animal Health Corporation currently has an average rating of “Hold” and an average price target of $30.86.

Shares of Phibro Animal Health Corporation (NASDAQ:PAHC) traded down 2.47% during trading on Wednesday, hitting $38.28. The company had a trading volume of 86,352 shares. Phibro Animal Health Corporation has a 52 week low of $20.14 and a 52 week high of $40.25. The company has a market capitalization of $1.52 billion, a P/E ratio of 23.78 and a beta of 1.35. The stock’s 50-day moving average price is $38.43 and its 200 day moving average price is $32.86.

TRADEMARK VIOLATION NOTICE: “Bank of America Corporation Reiterates “Underperform” Rating for Phibro Animal Health Corporation (PAHC)” was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/08/23/phibro-animal-health-corporation-pahc-coverage-initiated-by-analysts-at-bank-of-america-corporation.html.

In related news, insider Jack Bendheim sold 48,000 shares of the stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $35.62, for a total transaction of $1,709,760.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Daniel M. Bendheim sold 1,443 shares of the stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $40.05, for a total transaction of $57,792.15. Following the sale, the vice president now owns 300 shares in the company, valued at approximately $12,015. The disclosure for this sale can be found here. Insiders sold a total of 316,657 shares of company stock worth $11,466,663 in the last quarter. 48.09% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Comerica Bank boosted its position in Phibro Animal Health Corporation by 3.5% in the first quarter. Comerica Bank now owns 21,578 shares of the company’s stock valued at $647,000 after buying an additional 734 shares during the period. Bank of New York Mellon Corp boosted its position in Phibro Animal Health Corporation by 13.3% in the first quarter. Bank of New York Mellon Corp now owns 347,657 shares of the company’s stock valued at $9,769,000 after buying an additional 40,735 shares during the period. Algert Global LLC boosted its position in Phibro Animal Health Corporation by 32.9% in the first quarter. Algert Global LLC now owns 64,684 shares of the company’s stock valued at $1,818,000 after buying an additional 16,013 shares during the period. Chicago Equity Partners LLC bought a new position in Phibro Animal Health Corporation during the first quarter valued at about $376,000. Finally, Great West Life Assurance Co. Can boosted its position in Phibro Animal Health Corporation by 7.3% in the first quarter. Great West Life Assurance Co. Can now owns 26,554 shares of the company’s stock valued at $745,000 after buying an additional 1,802 shares during the period. Hedge funds and other institutional investors own 47.64% of the company’s stock.

Phibro Animal Health Corporation Company Profile

Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.

Analyst Recommendations for Phibro Animal Health Corporation (NASDAQ:PAHC)

Receive News & Ratings for Phibro Animal Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.